Where has all the botox gone? (how) will we ever learn... using monoclonal antibodies to track botulinum toxin.
Botulinum toxin (BTX) is an important therapeutic tool in the treatment of overactive skeletal and smooth muscles, as well as hypersecretory and painful disorders. Despite advances in our understanding of how BTX works, much remains to be elucidated, such as how BTX ameliorates pain, how it produces weakness remote from the site of injection and the fate of the heavy and light chain components of the BTX molecule following endocytosis into the presynaptic membrane. BTX, conjugated to radionuclides, allows investigators to track the molecule both in vitro and in vivo. However, altering the BTX molecule may cause structural changes or pharmacokinetic and pharmacodynamic alterations, and disrupt its normal action. We propose instead to bind the biomarkers (appropriate dyes, radionuclides or MRI contrast agents) to monoclonal antibodies directed against either heavy or light chain components of BTX, thus allowing administration of native (i.e. unaltered) BTX.
Lim
Erle C-H
EC
Division of Neurology, Yong Loo Lin School of Medicine, National University of Singapore/National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Singapore. mdcelch@nus.edu.sg
Oh
Vernon M S
VM
Ong
Benjamin K C
BK
Chow
Adeline W L
AW
Seet
Raymond C S
RC